We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
On November 9, 2010, federal prosecutors indicted a retired associate general counsel of GlaxoSmithKline on criminal charges of obstruction and making false statements in connection with a Food and Drug Administration (FDA) investigation into alleged "off-label" promotion of a prescription drug product
